Zura Bio (ZURA) Common Equity (2021 - 2026)

Zura Bio's Common Equity history runs 6 years deep, the most recent figure standing at $216.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 55.21% year-over-year to $216.9 million in Q1 2026; TTM through Mar 2026 was $216.9 million, a 55.21% increase from a year earlier, with the FY2025 full-year figure at $101.5 million, down 31.56% from the prior year.
• Common Equity advanced to $216.9 million in Q1 2026 per ZURA's latest filing, from $101.5 million in the prior quarter.
• Across five years, Common Equity topped out at $216.9 million in Q1 2026 and bottomed at -$32.1 million in Q4 2022.
• The 5-year median for Common Equity is $70.4 million (2023), against an average of $81.5 million.
• Across the five-year window, Common Equity slumped 249.16% in 2022 and surged 935.19% in 2023, its largest moves.
• Year by year, Common Equity stood at -$32.1 million in 2022, then jumped by 289.89% to $60.9 million in 2023, then surged by 143.72% to $148.4 million in 2024, then plunged by 31.56% to $101.5 million in 2025, then surged by 113.61% to $216.9 million in 2026.
• Per Business Quant, the three latest ZURA Common Equity figures stand at $216.9 million (Q1 2026), $101.5 million (Q4 2025), and $109.8 million (Q3 2025).